+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Codexis Inc (CDXS) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • April 2023
  • GlobalData
  • ID: 4286378
Codexis Inc (CDXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Codexis Inc (Codexis) is a protein engineering company, which discovers, develops and markets synthetic proteins for a wide range of applications. It sells biocatalysts for the commercial manufacture of pharmaceuticals and industrial enzymes and fine chemicals, and enzymes as biotherapeutics and for use in molecular diagnostics. The company identifies, optimizes and produces enzymes by using CodeEvolver, its proprietary protein engineering technology platform, which introduces mutation into genes to transform the enzymes that they produce. It also offers a range of biocatalyst solutions including robotic high-throughput screening, organic chemistry and process development, and genomic sequencing. The company serves pharmaceutical, food manufacturing, agricultural feed, consumer care, and chemical companies. Codexis is headquartered in Redwood City, California, the US.

Codexis Inc Key Recent Developments

  • Apr 19, 2023: Codexis announces RNA Therapeutics manufacturing workshop at TIDES USA
  • Apr 04, 2023: Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
  • Feb 23, 2023: Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
  • Feb 22, 2023: Codexis announces several key presentations from its gene therapy programs at 19th Annual WORLDSymposium

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Codexis Inc - Key Facts
  • Codexis Inc - Key Employees
  • Codexis Inc - Key Employee Biographies
  • Codexis Inc - Major Products and Services
  • Codexis Inc - History
  • Codexis Inc - Company Statement
  • Codexis Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Codexis Inc - Business Description
  • Business Segment: Novel Biotherapeutics
  • Overview
  • Performance
  • Business Segment: Performance Enzymes
  • Overview
  • Performance
  • Geographical Segment: Americas
  • Performance
  • Geographical Segment: APAC
  • Performance
  • Geographical Segment: EMEA
  • Performance
  • R&D Overview
  • Codexis Inc - Corporate Strategy
  • Codexis Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Codexis Inc - Strengths
  • Codexis Inc - Weaknesses
  • Codexis Inc - Opportunities
  • Codexis Inc - Threats
  • Codexis Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Codexis Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 19, 2023: Codexis announces RNA Therapeutics manufacturing workshop at TIDES USA
  • Apr 04, 2023: Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
  • Feb 23, 2023: Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
  • Feb 22, 2023: Codexis announces several key presentations from its gene therapy programs at 19th Annual WORLDSymposium
  • Jan 23, 2023: Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
  • Dec 20, 2022: Codexis Announces Appointment of H. Stewart Parker to Board of Directors
  • Nov 29, 2022: Codexis provides update on prioritized corporate strategy
  • Nov 01, 2022: Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
  • Oct 03, 2022: Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
  • Oct 03, 2022: Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Codexis Inc, Key Facts
  • Codexis Inc, Key Employees
  • Codexis Inc, Key Employee Biographies
  • Codexis Inc, Major Products and Services
  • Codexis Inc, History
  • Codexis Inc, Subsidiaries
  • Codexis Inc, Key Competitors
  • Codexis Inc, Ratios based on current share price
  • Codexis Inc, Annual Ratios
  • Codexis Inc, Interim Ratios
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Codexis Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Codexis Inc, Performance Chart (2018 - 2022)
  • Codexis Inc, Ratio Charts
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Codexis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takasago International Corporation (U.S.A.)
  • Solvias Inc
  • Royal DSM NV
  • Novozymes AS
  • evocatal GmbH
  • c-LEcta GmbH
  • Cambrex Corp
  • Bayer AG
  • BASF SE
  • Almac Group Ltd
  • Novozymes AS
  • Almac Group Ltd
  • BASF SE
  • c-LEcta GmbH
  • Solvias Inc
  • Bayer AG
  • Takasago International Corporation (U.S.A.)
  • Royal DSM NV
  • evocatal GmbH
  • Cambrex Corp